Matthew D. Hall

18.2k citations

178 papers · 11.5k indexed · 7 hit papers · h-index 51

Impact in

Oncology top 0.2%
- Metal complexes synthesis and properties
- Drug Transport and Resistance Mechanisms
Infectious Diseases top 1%
- SARS-CoV-2 and COVID-19 Research

Papers in

Oncology 83
- Drug Transport and Resistance Mechanisms 36
- Metal complexes synthesis and properties 32
Infectious Diseases 26
- SARS-CoV-2 and COVID-19 Research 17
- COVID-19 Clinical Research Studies 14

Co-authors: Michael M. Gottesman Trevor W. Hambley Kristen M. Pluchino Ding‐Wu Shen Robert W. Robey Susan E. Bates Antonio Tito Fojo Lynn M. Pouliot
Journals: Journal of Medicinal Chemistry (9 papers)Journal of Biological Chemistry (6 papers)ACS Pharmacology & Translational Science (6 papers)Cancer Research (5 papers)Molecular Cancer Therapeutics (5 papers)
Partner nations: United States Australia Sweden

In The Last Decade

Matthew D. Hall

171 papers receiving 11.4k citations

Hit Papers

7 papers align trajectories log scale

The ferroptosis inducing compounds RSL3 and ML162 are not direct inhibitors of GPX4 but of TXNRD1 2023 · 127 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2023 Redox Biology
2023 Nature Reviews Drug Discovery
2020 ACS Central Science
2018 Nature reviews. Cancer
2017 Nature Communications
2012 Pharmacological Reviews
2002 Coordination Chemistry Reviews

Peers

Countries citing papers authored by Matthew D. Hall

Since Specialization

Citations

This map shows the geographic impact of Matthew D. Hall's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew D. Hall with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew D. Hall more than expected).

Fields of papers citing papers by Matthew D. Hall

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthew D. Hall. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew D. Hall. The network helps show where Matthew D. Hall may publish in the future.

Co-authors

The 25 scholars most cited alongside Matthew D. Hall, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Matthew D. Hall Line = papers co-authored together Matthew D. Hall links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Systematic evaluation of Tox21 compounds that target β-adrenergic receptors and their role in cardiotoxicity Toxicology and Applied Pharmacology ·Xi Luo, Li Zhang, Srilatha Sakamuru, Barbara J. Culliton, Jinghua Zhao, Menghang Xia, Tuan Xu, Deborah K. Ngan, Jameson Travers, Simon Wood, И В Волков, Vincent X Z Kwok, Carleen Klumpp‐Thomas, Stephen Ferguson, Hu Zhu, Matthew D. Hall, David M. Reif, Ruili Huang	2025	0
2	Simulations and active learning enable efficient identification of an experimentally-validated broad coronavirus inhibitor Nature Communications ·Emad Suleiman Alwan, Tim Hempel, Jonathan H. Shrimp, Nina Moor, Lluı́s Raich, Cheila Rocha, Robin Winter, Tuan Le, Stefan Pöhlmann, Markus Hoffmann, Matthew D. Hall, Frank Noé	2025	0
3	Development of a high‐throughput dual‐stream liquid chromatography–tandem mass spectrometry method to screen for inhibitors of glutamate carboxypeptidase II Rapid Communications in Mass Spectrometry ·Chia Li Song, W. A. Wildhack, Stephen C. Kales, 苏志民, Xin Hu, Cheng Junfeng, Franck Tinland, B. Eswar, Takashi Tsukamoto, Huijun Wei, Barbara S. Slusher, John Janiszewski, Matthew D. Hall	2024	2
4	Novel Therapeutic Strategies Exploiting the Unique Properties of Neuroendocrine Neoplasms Cancers ·Renée McCauley, Luigi Scotto, Thomas Litman, Srinath Mote, Hu Zhu, Min Shen, Robert W. Robey, Matthew D. Hall, Tito Fojo, Susan E. Bates	2023	1
5	Discovery of Novel Small-Molecule Scaffolds for the Inhibition and Activation of WIP1 Phosphatase from a RapidFire Mass Spectrometry High-Throughput Screen ACS Pharmacology & Translational Science ·Jenna Forster, Yuhong Fang, Dingyin Tao, Hui-biao, Hongmao Sun, Veronica Sanchez-Ortega, Karavadhi Surendra, Kelly Lane, Zhendan Shi, Olga Vasalatiy, Christopher A. LeClair, Н.В. Терешко, Min Shen, Samarjit Patnaik, Ettore Appella, Nathan P. Coussens, Matthew D. Hall, Daniel H. Appella	2022	7
6	Virtual Screening for the Discovery of Microbiome β-Glucuronidase Inhibitors to Alleviate Cancer Drug Toxicity Journal of Chemical Information and Modeling ·Anup P. Challa, Xin Hu, Yaqin Zhang, Jeffrey L. Hymes, Bret D. Wallace, Karavadhi Surendra, Hongmao Sun, Samarjit Patnaik, Matthew D. Hall, Min Shen	2022	9
7	GPC1-Targeted Immunotoxins Inhibit Pancreatic Tumor Growth in Mice via Depletion of Short-lived GPC1 and Downregulation of Wnt Signaling Molecular Cancer Therapeutics ·Jiajia Pan, Nan Li, Alex Renn, Hu Zhu, Lu Chen, Min Shen, Matthew D. Hall, Min Qian, Ira Pastan, Mitchell Ho	2022	8
8	Minimal information for chemosensitivity assays (MICHA): a next-generation pipeline to enable the FAIRification of drug screening experiments Briefings in Bioinformatics ·Ziaurrehman Tanoli, Jehad Aldahdooh, فاطمه ابراهیمی فینی, Yinyin Wang, Jessica Minahan, Maddalena Fratelli, Cheng Fang, Marián Hajdúch, Florence Biétrix, Philip Gribbon, Andrea Zaliani, Matthew D. Hall, Min Shen, Kyle R. Brimacombe, Evgeny Kulesskiy, Jani Saarela, Krister Wennerberg, Markus Vähä‐Koskela, Jing Tang	2021	8
9	Hybrid In Silico Approach Reveals Novel Inhibitors of Multiple SARS-CoV-2 Variants ACS Pharmacology & Translational Science ·Sankalp Jain, Lukáš Zákora, Bolormaa Baljinnyam, Talal Asad, Quinlin Hanson, Wei Zhu, Miao Xu, Catherine Z. Chen, Wei Zheng, Xin Hu, Min Shen, Ganesha Rai, Matthew D. Hall, Anton Simeonov, Alexey Zakharov	2021	10
10	Effect of D614G Spike Variant on Immunoglobulin G, M, or A Spike Seroassay Performance The Journal of Infectious Diseases ·Carleen Klumpp‐Thomas, Heather Kalish, Jennifer Hicks, Jennifer Mehalko, Matthew Drew, Matthew J. Memoli, Matthew D. Hall, Dominic Esposito, Kaitlyn Sadtler	2020	18
11	Keeping It Clean: The Cell Culture Quality Control Experience at the National Center for Advancing Translational Sciences SLAS DISCOVERY ·Jacob S. Roth, Tobie D. Lee, Dorian M. Cheff, Maya L. Gosztyla, 正巳小野寺, Carina Danchik, Sam Michael, Anton Simeonov, Carleen Klumpp‐Thomas, Kelli M. Wilson, Matthew D. Hall	2020	6
12	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein Molecular Pharmacology ·Tobie D. Lee, Olivia W. Lee, Kyle R. Brimacombe, Lu Chen, Rajarshi Guha, Sabrina Lusvarghi, 椛沢宏之, Carleen Klumpp‐Thomas, Robert W. Robey, Suresh V. Ambudkar, Min Shen, Michael M. Gottesman, Matthew D. Hall	2019	22
13	Avoiding Fluorescence Assay Interference—The Case for Diaphorase Assay and Drug Development Technologies ·Matthew D. Hall, Anton Simeonov, Mindy I. Davis	2016	17
14	Diaphorase Coupling Protocols for Red-Shifting Dehydrogenase Assays Assay and Drug Development Technologies ·Mindy I. Davis, Min Shen, Anton Simeonov, Matthew D. Hall	2016	16
15	Specific Design of Titanium(IV) Phenolato Chelates Yields Stable and Accessible, Effective and Selective Anticancer Agents Chemistry - A European Journal ·Sigalit Meker, Ori Braitbard, Matthew D. Hall, Jacob Hochman, Edit Y. Tshuva	2016	5
16	Say No to DMSO: Dimethylsulfoxide Inactivates Cisplatin, Carboplatin, and Other Platinum Complexes Cancer Research ·Matthew D. Hall, Katherine A. Telma, Kenny Pang, Tobie D. Lee, James P. Madigan, John R. Lloyd, Ian S. Goldlust, James D. Hoeschele, Michael M. Gottesman	2014	293
17	The Protein Phosphatase 2A Inhibitor LB100 Sensitizes Ovarian Carcinoma Cells to Cisplatin-Mediated Cytotoxicity Molecular Cancer Therapeutics ·Kenny Pang, Bih‐Rong Wei, James P. Madigan, Matthew D. Hall, Richard J. Simpson, Zhengping Zhuang, Michael M. Gottesman	2014	39
18	Cisplatin Sensitivity Mediated by WEE1 and CHK1 Is Mediated by miR-155 and the miR-15 Family Cancer Research ·Lynn M. Pouliot, Yu‐Chi Chen, Kabilova D.K., Rajarshi Guha, Scott E. Martin, Michael M. Gottesman, Matthew D. Hall	2012	84
19	Identification of Compounds Selectively Killing Multidrug-Resistant Cancer Cells Cancer Research ·Dóra Türk, Matthew D. Hall, Benjamin F. Chu, Joseph A. Ludwig, Henry M. Fales, Michael M. Gottesman, Gergely Szakács	2009	87
20	Profiling SLCO and SLC22 genes in the NCI-60 cancer cell lines to identify drug uptake transporters Molecular Cancer Therapeutics ·Mitsunori Okabe, Gergely Szakács, Mark A. Reimers, Toshihiro Suzuki, Matthew D. Hall, Takaaki Abe, John N. Weinstein, Michael M. Gottesman	2008	124

About Matthew D. Hall

Matthew D. Hall is a scholar working on Oncology, Infectious Diseases, Computational Theory and Mathematics, Molecular Biology and Biochemistry, having authored 178 papers that have together received 11.5k indexed citations. Recurring topics across this work include Drug Transport and Resistance Mechanisms (36 papers), Metal complexes synthesis and properties (32 papers), Computational Drug Discovery Methods (19 papers), Pharmacological Effects and Toxicity Studies (19 papers), SARS-CoV-2 and COVID-19 Research (17 papers), COVID-19 Clinical Research Studies (14 papers), Lanthanide and Transition Metal Complexes (12 papers) and Click Chemistry and Applications (8 papers). The work is most often cited by research in Oncology (5.3k citations), Infectious Diseases (1.4k citations), Organic Chemistry (2.2k citations), Biomaterials (936 citations) and Molecular Biology (4.9k citations). Matthew D. Hall has collaborated with scholars based in United States, Australia and Sweden. Frequent co-authors include Michael M. Gottesman, Trevor W. Hambley, Kristen M. Pluchino, Ding‐Wu Shen, Robert W. Robey, Susan E. Bates, Antonio Tito Fojo, Lynn M. Pouliot, Anton Simeonov and Min Shen. Their work appears in journals such as Journal of Medicinal Chemistry, Journal of Biological Chemistry, ACS Pharmacology & Translational Science, Cancer Research and Molecular Cancer Therapeutics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact